ArticleCancer medicine2026
Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionTreatment strategies for advanced non-small cell lung cancer (aNSCLC) have evolved, but little is known about real-world approaches by biomarker groups across different lines of therapy (LOTs), particularly regarding discontinuation rates as a measure of effectiveness and tolerability.
methodsUsing deidentified patient data from the Flatiron Health electronic health record-derived database, we constructed a retrospective cohort study of aNSCLC patients diagnosed between January 2016 and June 2020, with follow-up through August 2023. Patients had either anaplastic lymphoma kinase (ALK) rearrangements or epidermal growth factor receptor (EGFR) mutations or had programmed cell death-ligand 1 (PD-L1) biomarker results (PD-L1 < 1%, 1%-49%, or ≥ 50%). For each biomarker group, we summarized treatments received across up to the sixth LOT, calculating the overall discontinuation rate and the rate due to death.
resultsThere were 13,369 patients in our sample (427 patients with ALK rearrangements, 2283 with EGFR mutations, 3663 PD-L1 < 1%, 3281 PD-L1 1%-49%, and 3715 PD-L1 ≥ 50%). Treatment patterns varied across biomarker groups. The overall discontinuation rate after first-line therapy was 31.9% for ALK-rearrangement, 39.5% for EGFR-mutation, and ranged from 50.6% to 57.5% for the PD-L1 groups. The discontinuation rate due to death after first-line therapy was 8% (ALK-rearrangement), 14.8% (EGFR-mutation), and approximately 21% for the three PD-L1 groups. Patients with gene alterations had lower overall discontinuation rates across second through fifth LOTs than those without.
conclusionsPatients with driver alterations had lower overall discontinuation rates in subsequent therapy lines, highlighting the need for effective, tolerable treatments for those without driver alterations. Notably, a substantial proportion of patients with targetable driver alterations did not receive the corresponding TKI, underscoring real-world gaps in biomarker-directed treatment implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.